company background image
APOP

Cellect BiotechnologyNasdaqCM:APOP Stock Report

Market Cap

US$21.0m

7D

-7.6%

1Y

142.8%

Updated

27 Sep, 2021

Data

Company Financials
APOP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

APOP Overview

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel.

Price History & Performance

Summary of all time highs, changes and price drops for Cellect Biotechnology
Historical stock prices
Current Share PriceUS$21.37
52 Week HighUS$6.60
52 Week LowUS$35.52
Beta1.86
1 Month Change27.51%
3 Month Change45.57%
1 Year Change142.84%
3 Year Change-76.57%
5 Year Change-76.70%
Change since IPO-78.61%

Recent News & Updates

Shareholder Returns

APOPUS Life SciencesUS Market
7D-7.6%-1.1%2.0%
1Y142.8%49.1%32.8%

Return vs Industry: APOP exceeded the US Life Sciences industry which returned 49.1% over the past year.

Return vs Market: APOP exceeded the US Market which returned 32.8% over the past year.

Price Volatility

Is APOP's price volatile compared to industry and market?
APOP volatility
APOP Beta1.86
Industry Beta0.97
Market Beta1

Stable Share Price: APOP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: APOP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198612Shai Yarkonihttps://www.cellect.co

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in’s identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells.

Cellect Biotechnology Fundamentals Summary

How do Cellect Biotechnology's earnings and revenue compare to its market cap?
APOP fundamental statistics
Market Cap₪67.08m
Earnings (TTM)-₪16.57m
Revenue (TTM)n/a

0x

P/S Ratio

-4.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APOP income statement (TTM)
Revenue₪0
Cost of Revenue₪0
Gross Profit₪0
Expenses₪16.57m
Earnings-₪16.57m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-16.90
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did APOP perform over the long term?

See historical performance and comparison

Valuation

Is Cellect Biotechnology undervalued compared to its fair value and its price relative to the market?

11.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APOP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APOP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APOP is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: APOP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APOP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APOP is overvalued based on its PB Ratio (11.7x) compared to the US Life Sciences industry average (5.9x).


Future Growth

How is Cellect Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

8.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cellect Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cellect Biotechnology performed over the past 5 years?

2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APOP is currently unprofitable.

Growing Profit Margin: APOP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APOP is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare APOP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APOP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (56.9%).


Return on Equity

High ROE: APOP has a negative Return on Equity (-289.46%), as it is currently unprofitable.


Financial Health

How is Cellect Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: APOP's short term assets (₪9.9M) exceed its short term liabilities (₪3.3M).

Long Term Liabilities: APOP's short term assets (₪9.9M) exceed its long term liabilities (₪2.8M).


Debt to Equity History and Analysis

Debt Level: APOP is debt free.

Reducing Debt: APOP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APOP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: APOP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.4% each year


Dividend

What is Cellect Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APOP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APOP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APOP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APOP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APOP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Shai Yarkoni (63 yo)

8.17yrs

Tenure

₪1,751,000

Compensation

Dr. Shai Yarkoni, M.D., Ph D., co-founded Cellect Biotherapeutics subsidiary of Cellect Biotechnology Ltd. in 2011.He has been the Chief Executive Officer of Cellect Biotechnology Ltd. since July 04, 2013...


CEO Compensation Analysis

Compensation vs Market: Shai's total compensation ($USD546.93K) is about average for companies of similar size in the US market ($USD546.08K).

Compensation vs Earnings: Shai's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: APOP's management team is seasoned and experienced (5.7 years average tenure).


Board Members

Experienced Board: APOP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cellect Biotechnology Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cellect Biotechnology Ltd.
  • Ticker: APOP
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.952m
  • Shares outstanding: 980.43k
  • Website: https://www.cellect.co

Number of Employees


Location

  • Cellect Biotechnology Ltd.
  • 23 Hata’as Street
  • Kfar Saba
  • 44425
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 23:06
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.